PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “GINGIVAL HYPERPLASIA”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 145 records · Page 8Linked to original sources
PubMed1997

Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine.

Patients with nifedipine-induced gingival hyperplasia (GH) often require continued calcium channel blocker therapy. Switches to diltiazem and verapamil have been described; however, these drugs are of a different chemical class and present therapeutic limitations in some patients. The purpose of this study was to evaluate the effect on nifedipine-induced GH of a switch to a dihydropyridine derivative with a low incidence of GH. Fourteen patients with nifedipine-induced GH were given a medical exam and a periodontal exam. The following parameters were assessed: probing depth (PD), gingival margin (GM), gingival thickness (GT), plaque index (PI), and gingival index (GI). Intraoral photographs, study models, and a gingival biopsy for histological examination were taken. Following baseline measures, patients were randomized to continued treatment with nifedipine or an equivalent dose of isradipine in a single-blind fashion. Biweekly periodontal parameters were taken for 8 weeks. At the end of 8 weeks, some patients elected to receive 4 weeks of open label isradipine therapy, with biweekly examination continuing through the open label phase. The isradipine treatment arm showed a mean decrease in PD of 0.59 mm at week 8 (P < 0.05). No other measured parameter (GM, GT, PI, GI) was significantly changed, compared either to baseline or to the alternate treatment arm. Clinically, 60% of patients treated with isradipine exhibited a decrease in hyperplasia, while 66% of patients treated with nifedipine demonstrated an increase in hyperplasia, a significant difference (P < 0.05). When combined with open label data, patients switching therapy to isradipine exhibited an increase in GM (increase in recession) of 0.74 mm from baseline to week 12 (P < 0.05). No patients treated with isradipine exhibited an increase in gingival overgrowth. All patients exhibited adequate control of hypertension. We conclude that in hypertensive patients with nifedipine-induced GH, switching hypertensive therapy to isradipine may result in a regression of GH. When coupled with aggressive oral hygiene treatment, this drug may provide a reasonable option for patients requiring dihydropyridine treatment.

Adult↗
PubMed2005

Amelogenesis imperfecta and unusual gingival hyperplasia.

BACKGROUND: Amelogenesis imperfecta (AI) is a group of hereditary conditions that primarily involves the defective formation and/or calcification of enamel. The association of AI with gingival enlargement-like lesions has also been reported. METHODS: This paper reports a case of a hypoplastic AI associated with unusual generalized gingival hyperplasia. RESULTS: Histological aspect of the gingival growth was characterized by a dense connective tissue with a mild mononuclear inflammatory infiltrate, calcified bodies, and islands of odontogenic epithelium. CONCLUSION: The present case represents a very interesting demonstration of the fact that, although rare, AI may be associated with generalized gingival enlargement.

Adolescent↗
PubMed1989

Drug-induced gingival hyperplasia. Selective review of the literature and a photometric assessment technique.

Several drugs share the side effect of inducing gingival hyperplasia in a substantial percentage of patients. A selective review of the literature as well as possible mechanisms for the causation of gingival overgrowth by these drugs is offered. In addition, a photometric technique for assessing gingival overgrowth is described and compared with a previously used method.

Adolescent↗
PubMed1991

[Gingival hyperplasia in a heart transplant patient treated with cyclosporin A and nifedipine].

Cyclosporin-A and Nifedipine-induced gingival enlargement have been reported to have similar clinical and histopathological features as phenytoin. The present case report describes the clinical course and treatment of a young heart-transplant patient who developed gingival hyperplasia under both Nifedipine and Cyclosporin-A. After withdrawing Nifedipine from his daily medication and a second step of surgical excision, the patient presents no recurrence of gingival enlargement, 6 months post-treatment despite his Cyclosporin-A regimen and poor oral hygiene.

Adolescent↗
PubMed1993

Ultrastructural features of cyclosporine A-induced gingival hyperplasia.

The present work collected data on the ultrastructural features of the attached gingiva in kidney transplant patients who showed gingival hyperplasia following cyclosporin A (Cy A) treatment. Ultrastructural examination was carried out on biopsies of attached gingiva obtained from 8 male patients (30 to 60 years old) undergoing treatment at the Dental Clinic of the University of Ferrara. The data showed that, although many fibroblasts are present in Cy A-induced hyperplasia, there is a particular abundance of amorphous substance compared to fibrous, as well as marked plasma cell infiltration. On the basis of the data collected, we hypothesize that the morphological features of the dimensional increase in gingival tissue associated with Cy A treatment in kidney transplant patients may be considered local manifestations of a systemic phenomenon.

Adult↗
PubMed2005

Facial distortion secondary to idiopathic gingival hyperplasia: surgical management and oral reconstruction with endosseous implants.

Little information exists regarding the surgical and oral reconstructive options for the patient with idiopathic gingival hyperplasia, especially with regard to endosseous implant placement and recurrence of the disease. The authors report a case of severe gingival enlargement and bone resorption involving the maxillary and mandibular arches in a 21-year-old female causing distortion of facial features. The etiology could not be established but the condition was exacerbated during pregnancy, causing chewing, speaking, and esthetic problems. The hyperplastic tissue and all the teeth were removed surgically, followed by immediate placement of 2 endosseous implants. Restoration of esthetics and function with a maxillary denture and mandibular overdenture were completed 3 months later. No disease recurrence was noted at the 6-month postoperative interval.

Adult↗
PubMed1988

The CO2 laser in the excision of gingival hyperplasia caused by nifedipine.

The CO2 laser has been shown to have decided advantages over conventional techniques in the excision of gingival hyperplasia. These advantages include accurate debulking without bleeding and simultaneous sterilization. In addition, post-operative pain and discomfort are considerably reduced. This is particularly important in patients being treated with nifedipine for cardiac disease. A case study which demonstrates these issues is presented.

Adult↗
PubMed1989

[Mast cell counting in fibrous gingival hyperplasias and giant cell granuloma].

Mast cells are the normal components of the connective tissues and they are found particularly in perivascular areas. They have a primary role in hypersensitivity reactions and inflamatuar process. They are found in whole healthy and inflamed periodontal tissues. Number of mast cells increase in some connective tissue tumors. However the roles of mast cells in fibrous gingival hyperplasias and giant cell granulomas of gingiva, is not clear. In this study, the number of mast cells were counted in both lesion groups. Numbers of mast cells were found increased on gingival fibrous hyperplasias, comparing to normal connective tissues and giant cell granulomas.

Adult↗
PubMed1998

[Drug-induced gingival hyperplasia].

A case report is presented, which describes a kidney-transplant recipient medicated simultaneously with both cyclosporin A and nifedipine and who developed an extreme form of gingival hyperplasia. Repeated dental-surgical treatments provided only temporary regression of the gingival overgrowth, however, after discontinuation of the calcium channel blocker there was a significant improvement of the hyperplasia that no longer required specific dental treatment. The prevalence and mechanisms of this side effect in solid-organ transplant recipients on cyclosporin therapy is discussed. Treatment consists in the discontinuation of potentiating factors like calcium channel blockers and possibly also a dose reduction of cyclosporin, which together may support or reduce the need of dental-surgical procedures.

Adult↗
PubMedDate not supplied

[Gingival hyperplasia from calcium antagonists].

The Authors have studied a sample of forty-four patients suffering from cardiovascular pathology treated with calcium-antagonist. They have evaluated the incidence and clinical-histological characteristics of gingival hyperplasia.

Calcium Channel Blockers↗